• Record: found
  • Abstract: found
  • Article: not found

Bortezomib in mantle cell lymphoma.

Future oncology (London, England)

Treatment Outcome, Recurrence, therapeutic use, pharmacology, Pyrazines, Protease Inhibitors, Middle Aged, Male, drug therapy, Lymphoma, Mantle-Cell, Humans, Female, Clinical Trials as Topic, Boronic Acids, Antineoplastic Agents, Aged

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyperfractionated cyclophosphamide, vincristine, adriamycin/doxorubicin and dexamethasone/rituximab. Most patients still relapse and a multitude of novel agents are currently being tested in this setting, including proteasome inhibitors with bortezomib (the first of its class and the first US FDA-approved drug for MCL), mTOR inhibitors, Bcl-2 inhibitors, antiangiogenesis agents and histone deacetylase inhibitors among others. An obvious effort is needed to enroll patients on clinical trials, the design of which might benefit from pharmacogenomics and a better understanding of MCL biology and its diversity.

      Related collections

      Author and article information



      Comment on this article